Bibliography 2021 Takao Takeshima (2021年論文業績)

 英文原著

1) Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD.  Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 2021;61(6): 927-935.

https://www.ncbi.nlm.nih.gov/pubmed/34153117

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361926/pdf/HEAD-61-927.pdf
 

2)  Hirata K, Sakai F, Takeshima T, Imai N, Matsumori Y, Yoshida R, Numachi Y, Peng C, Mikol DD, Cheng S.
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial. J Headache Pain. 2021;22(1): 110.

https://www.ncbi.nlm.nih.gov/pubmed/34537006
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449906/pdf/10194_2021_Article_1313.pdf

3)  Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, Nelson AM, Han Y, Jaffe DH, Matsumori Y, Takeshima T.
Comprehensive population-based survey of migraine in Japan: results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study.
Curr Med Res Opin. 2021; 37(11):1945-1955.

https://www.ncbi.nlm.nih.gov/pubmed/34429000
https://www.tandfonline.com/doi/full/10.1080/03007995.2021.1971179

 
4)  Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T, Ning X, Shima T, Ishida M, Iba K, Kondo H, Koga N.
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Headache 2021;61(7): 1092-1101.

https://www.ncbi.nlm.nih.gov/pubmed/34324700

https://headachejournal.onlinelibrary.wiley.com/doi/epdf/10.1111/head.14169

 
5) Suzuki K, Takeshima T, Igarashi H, Imai N, Danno D, Yamamoto T, Nagata E, Haruyama Y, Mitsufuji T, Suzuki S, Ito Y, Shibata M, Kowa H, Kikui S, Shiina T, Okamura M, Tatsumoto M, Hirata K.
Impact of the COVID-19 pandemic on migraine in Japan: a multicentre cross-sectional study.
J Headache Pain. 2021;22(1): 53.

https://www.ncbi.nlm.nih.gov/pubmed/34098873
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182734/pdf/10194_2021_Article_1263.pdf

 
6) Kubota T, Nabatame S, Sato R, Hama M, Nishiike U, Mochizuki H, Takahashi MP, Takeshima T. Hemiplegic migraine type 2 caused by a novel variant within the P-type ATPase motif in ATP1A2 concomitant with a CACNA1A variant.
Brain Dev. 2021;43(9): 952-957.

https://www.ncbi.nlm.nih.gov/pubmed/34092402
https://www.brainanddevelopment.com/article/S0387-7604(21)00100-5/fulltext
 

7) Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M.
Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
Headache 202;61(5): 755-765.

https://www.ncbi.nlm.nih.gov/pubmed/33990951
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252620/pdf/HEAD-61-755.pdf

8) Tatsuoka Y, Takeshima T, Ozeki A, Matsumura T.
Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase 2 Randomized Controlled Study.
Neurol Ther. 2021;10(1): 265-278.

https://www.ncbi.nlm.nih.gov/pubmed/33835383
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140173/pdf/40120_2021_Article_236.pdf

9)  Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, Peng C, Xue F, Mikol DD.
Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Headache 2021;61(4): 653-661.

https://www.ncbi.nlm.nih.gov/pubmed/33764538

https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14096

10)  Kano Y, Inui S, Uchida Y, Sakurai K, Muto M, Sugiyama H, Takeshima T, Yuasa H, Yamada K, Matsukawa N.
Quantitative arterial spin labeling magnetic resonance imaging analysis of reversible cerebral vasoconstriction syndrome: A case series.
Headache. 2021;61(4): 687-693.

https://www.ncbi.nlm.nih.gov/pubmed/33720415

11)  Hirata K, Takeshima T, Sakai F, Tatsuoka Y, Suzuki N, Igarashi H, Nakamura T, Ozeki A, Yamazaki H, Skljarevski V.
A long-term open-label safety study of galcanezumab in Japanese patients with migraine.
Expert Opin Drug Saf. 2021;20(6): 721-733.

https://www.ncbi.nlm.nih.gov/pubmed/33393835
https://www.tandfonline.com/doi/full/10.1080/14740338.2021.1866536